Section Arrow
Quote
INTS.NASDAQ
- Intensity Therapeutics Inc.
Quotes are at least 15-min delayed:2026/06/24 17:43 EDT
After Hours
Last
 4
-0.08 (-1.96%)
Bid
4
Ask
4.13
High 4.13 
Low 3.9883 
Volume 179 
Regular Hours (Closed)
Last
 4.08
+0.08 (+2.00%)
Day High 
4.12 
Prev. Close
4 
1-M High
4.76 
Volume 
152.60K 
Bid
4
Ask
4.13
Day Low
3.7996 
Open
3.8751 
1-M Low
3.51 
Market Cap 
10.81M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.79 
20-SMA 4 
50-SMA 4.64 
52-W High 43.5 
52-W Low 3.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.01/-2.70
Enterprise Value
10.89M
Balance Sheet
Book Value Per Share
3.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0095-0.0322-77.22%-- 
After Hours 0.0071 -0.0024 -25.26%
CALCCalciMedica0.5973-0.206-25.64%-- 
After Hours 0.6325 +0.0352 +5.89%
ABSIAbsci Corp10.075+2.665+35.96%-- 
After Hours 10.0109 -0.0641 -0.64%
EVGNEvogene Ltd.0.4392-0.0518-10.55%-- 
After Hours 0.415 -0.0242 -5.51%
HUMAHumacyte0.6977-0.0027-0.39%-- 
After Hours 0.7 +0.0023 +0.33%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.